Product Management & the FDA. Agenda/Scope What is different about managing products in a regulated industry? – Devices; Biologics; Pharma; Consumer goods;

Slides:



Advertisements
Similar presentations
Mary Ellen Turner MD, MPH Vice-President
Advertisements

Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
Drugs vs. Devices Jeng Mah & Gosford A Sawyerr Sept 16, 2005.
Parallel Session 1 The Role of the Statistician in Post- Marketing, Including Surveillance Organizers –Harry Bushar (FDA-CDRH) –Greg Campbell (FDA-CDRH)
1 HCMDSS Workshop PANEL 1: Design for Future Medical Devices November 16, 2004 Presentation by: Robert Kircher, Jr. Dose Safety Company P.O. Box
@ PMCQ October 14, Agenda l PAAB info l Common Review Issues l Current Initiatives l Trends.
The Statisticians Role in Pharmaceutical Development
@ PMCQ U October 19, Agenda l What is Advertising? l Pre-Launch Activities You Can Do l PAAB pre-NOC Meeting/Review policy.
CBER 510(k) Challenges and Strategies Susan Finneran Director of Clinical and Regulatory Affairs.
Agenda DUKE UNIVERSITY MEDICAL CENTER Department of Psychiatry and Behavioral Sciences Clinical Research within an EMR What the difference between an EMR.
Implementation - Medical Devices. Overview Act on Medical Devices – background and overview. Surveillance - Competent authority. Directive 93/42. Directive.
INFLUENCE OF CONSUMER PERCEPTION ON NEW FOOD PRODUCT DEVELOPMENT.
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
The Changing Food Environment The Role and Activities of the U.S. Food and Drug Administration Transatlantic Consumer Dialogue The Changing Food Environment.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Minnesota Alliance for Patient Safety Improving Regulation Discussion Operations Committee January 7, 2014.
For use by AICP conference attendees only. Not for use with the public. Association of Insurance Compliance Professionals May 17, 2013 Erin Mirza, Insurance.
INTRODUCTION TO RA.
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
Case Study: Pharmaceuticals Patrick F. Sullivan, Ph.D. 939 North Graham Avenue, Indianapolis, IN
The Science of Quality By Design Janet Woodcock, M.D. May 19, 2004.
The Role of the Research Office Joint Research & Enterprise Office (JREO) St George’s University of London and St George’s University Hospitals NHS Foundation.
Summary: Biological Therapeutics for Rare Plasma Protein Disorders Workshop July 21, 2005 Mark Weinstein, Ph.D. Office of Blood Research and Review CBER,
Commercialization of Cellular Therapies. Pharma & Biotech Growth Rates Have Been Declining Over The Last Decade Source: IMS Health 2008.
Risk Management Strategy for the Pharma and Biotech Product Lifecycle : New Regulatory and Legal Focus and Approach Morgan, Lewis & Bockius, LLP August.
The International Society For Cellular Therapy. Mission Statement ISCT is a global association driving the translation of scientific research to deliver.
Center for Biologics Evaluation and Research, FDA Kathryn M. Carbone, M.D. Associate Director for Research.
NAS/IOM Review of Rare Diseases Research and Orphan Products Development - USA Timothy Cote, M.D., MPH Director, Office of Orphan Products Development.
Yesterday’s talk: –Do not rely solely on intuition Today’s talk –Rely on scientific method (Stroop) –Scope of Psychology –Mind-body relation –More on scientific.
Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
1 Estimating CDER Resources Devoted to Safety Theresa M. Mullin, Ph.D. Office of Planning, Office of Commissioner April 15, 2005 Presentation to: FDA Science.
Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
Regulatory and Reimbursement Harmonization An Industry Perspective Adrian Griffin | April 2016.
“Your sustainable compliance and remediation partners”
Parting Shots IVD Roundtable 510(k) Workshop
Rachel Neubrander, PhD Division of Cardiovascular Devices
Clinical Review Process for New Drug Development and Application

FDA Perspective on Cardiovascular Device Development
CMS and FDA The History and Horizon of Regulatory Coordination
The FDA Early Feasibility Study Pilot and the Innovation Pathway
Introduction to Direct-to-Consumer Genetic Testing
American Society for Quality Region 5 Quality Conference
Marissa Kuzirian, PhD ‘15 Investment Manager
Clinical Trials in IBD.
Top 6 Strategies of Digital Marketing.
Evolution of Treatment Strategies Targeting IL-23 for Psoriasis
Clinical trial کارازمایی بالینی
Combination products The paradigm shift
Strategic & Operational Planning:
Positive Impacts of Developing Novel Endpoints Generated by Mobile Technology for Use in Clinical Trials* SPECIFIC BENEFITS   SHORT-TERM MEDIUM-TERM LONG-TERM.
IS4550 Security Policies and Implementation
Direct-To-Consumer Genetic Testing
Women’s Health Technologies CRN
Beyond Academia.
The Evolving Role of Immunotherapy in NSCLC
Progress Report on the Patient Reported Outcomes Harmonization Team
PhRMA Guiding Principles
Richelle Serrano Clindata Insight September 4-8, 2018
CA Compliance Law: Challenges for Industry
The International Drug Safety Paradigm
Lessons Learned from the Mistakes of Others
Bioprocess Engineer NOS Functional Map v4
Regulatory Perspective of the Use of EHRs in RCTs
DTC through Cision ID. Direct-to-consumer audiences.
Presentation transcript:

Product Management & the FDA

Agenda/Scope What is different about managing products in a regulated industry? – Devices; Biologics; Pharma; Consumer goods; Software What is the typical role for Product Manager? What is missing? What is possible?

What we actually talked about… Intros & backgrounds PM role in regulatory strategy Early engagement Points of overlapping interest (regulatory, marketing, quality) How to get early publishing and thought leadership without scaring regulatory What are your claims? The simple mater of coding & coverage Will DTC get rolled back? What labeling challenges does patient-specific therapy present? Biologics How does increased post-market surveillance effect PM?

What can go wrong? Regulatory group posture & biases Marketing ( v. ) Pre-launch education Identifying MAB Staking out a position

Shared Interests: Venn Diagram: FDA & PM Usability, human factors, Labeling for clinicians; labeling for patients Safety & efficacy Efficacy out-of box experience, compliance, technique, digital dexterity

Continuum of PM Expertise HF Lead Investigator recruitment Behavioral sciences Experiment design Bio-statistics

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.